View ValuationGenvor 将来の成長Future 基準チェック /06現在、 Genvorの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 23Genvor Incorporated Appoints Donald Kalkofen as Chief Financial OfficerGenvor Incorporated announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness. Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets. Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University.お知らせ • Feb 11Genvor, Inc. Announces the Publication of Peer-Reviewed Research Validated Its Proprietary Agm182 Antifungal Peptide Technology in PhytofrontiersGenvor Inc. announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™?, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture's Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contain corn and other crops, posing significant risks to human and animal health. Economic losses fromungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years. The peer-reviewed publication follows Genvor's November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology's commercial potential. The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor's over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination.お知らせ • Jan 28Genvor, Inc. Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, Effective February 2, 2026Genvor Inc. announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD.お知らせ • Dec 12Genvor Incorporated Auditor Raises 'Going Concern' DoubtGenvor Incorporated filed its 10-K on Dec 10, 2025 for the period ending Sep 30, 2025. In this report its auditor, Novogradac & Company LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Dec 06Genvor Incorporated announced that it expects to receive $7 million in fundingGenvor Incorporated announced that it will receive $70,00,000 in funding on December 5, 2025. The company will issue common shares and warrants in the transaction. The minimum investment accepted from any outside investor is $10,000. The company will issue securities pursuant to exemption provided under Regulation D.お知らせ • Aug 14Genvor Incorporated announced delayed 10-Q filingOn 08/13/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 13Genvor Incorporated announced delayed 10-Q filingOn 05/12/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 19Genvor Incorporated announced delayed 10-Q filingOn 02/18/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 01Genvor Incorporated announced delayed annual 10-K filingOn 01/31/2025, Genvor Incorporated announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Oct 23Genvor Incorporated Announces the Resignation of Judith S. Miller as Member of the Board of DirectorsOn August 7, 2024, Judith S. Miller resigned as a member of the Board of Directors of Genvor Incorporated (the Company).お知らせ • Aug 16Genvor Incorporated announced delayed 10-Q filingOn 08/15/2024, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 18Genvor Incorporated Appoints Judith Miller as Chief Business OfficerGenvor Incorporated announced Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer.お知らせ • Jan 17Genvor Incorporated Announces CEO ChangesGenvor Incorporated announced Chad Pawlak, Sr., global Agribusiness executive, has been appointed as Chief Executive Officer of Genvor, effective immediately. Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer. Chad Pawlak, Sr. brings over 30 years of experience with a proven track record of driving revenue growth and fostering strategic partnerships across agribusiness, regenerative agriculture, carbon marketing, food, and sustainability - particularly in soil and water conservation. He has a deep understanding of regenerative agriculture, biotechnology, crop cultivation, livestock management, dairy production, and consumer packaged goods (CPG). Most recently he was Chief Executive Officer of Locus Agricultural Solutions, an agricultural biological company, where he led the strategic growth plan through cross-functional collaboration, resulting in over 350,000 acres of enrollment in a nature-based carbon credit project utilizing a biological product as the practice change. Chad has previous experience as the U.S.-Canada Crop & Plant Protection Business Director Lead - Botanicals for MGK (a part of Valent USA & Sumitomo Chemical). In this role, he was responsible for the overall design of the strategic business plan of the $30 million Botanical & Organic Crop Protection segments in the U.S. & Canada. He holds an MBA from the Jack Welch Management Institute and BS & AOS in Marketing and Advertising/Public Relations from Johnson & Wales University. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Genvor は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:GNVR - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026N/A-1-1-1N/A12/31/2025N/A-1-1-1N/A9/30/2025N/A-6-1-1N/A6/30/2025N/A-600N/A3/31/2025N/A-600N/A12/31/2024N/A-7-1-1N/A9/30/2024N/A-3-1-1N/A6/30/2024N/A-4-1-1N/A3/31/2024N/A-3-1-1N/A12/31/2023N/A-3-1-1N/A9/30/2023N/A-2-1-1N/A6/30/2023N/A-1-1-1N/A3/31/2023N/A-1-1-1N/A12/31/2022N/A-4-1-1N/A9/30/2022N/A-5-1-1N/A3/31/2022N/A-5-1-1N/A12/31/2021N/A-3-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: GNVRの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: GNVRの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: GNVRの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: GNVRの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: GNVRの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: GNVRの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 01:48終値2026/05/19 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genvor Incorporated 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 23Genvor Incorporated Appoints Donald Kalkofen as Chief Financial OfficerGenvor Incorporated announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness. Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets. Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University.
お知らせ • Feb 11Genvor, Inc. Announces the Publication of Peer-Reviewed Research Validated Its Proprietary Agm182 Antifungal Peptide Technology in PhytofrontiersGenvor Inc. announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™?, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture's Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contain corn and other crops, posing significant risks to human and animal health. Economic losses fromungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years. The peer-reviewed publication follows Genvor's November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology's commercial potential. The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor's over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination.
お知らせ • Jan 28Genvor, Inc. Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, Effective February 2, 2026Genvor Inc. announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD.
お知らせ • Dec 12Genvor Incorporated Auditor Raises 'Going Concern' DoubtGenvor Incorporated filed its 10-K on Dec 10, 2025 for the period ending Sep 30, 2025. In this report its auditor, Novogradac & Company LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Dec 06Genvor Incorporated announced that it expects to receive $7 million in fundingGenvor Incorporated announced that it will receive $70,00,000 in funding on December 5, 2025. The company will issue common shares and warrants in the transaction. The minimum investment accepted from any outside investor is $10,000. The company will issue securities pursuant to exemption provided under Regulation D.
お知らせ • Aug 14Genvor Incorporated announced delayed 10-Q filingOn 08/13/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 13Genvor Incorporated announced delayed 10-Q filingOn 05/12/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 19Genvor Incorporated announced delayed 10-Q filingOn 02/18/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 01Genvor Incorporated announced delayed annual 10-K filingOn 01/31/2025, Genvor Incorporated announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Oct 23Genvor Incorporated Announces the Resignation of Judith S. Miller as Member of the Board of DirectorsOn August 7, 2024, Judith S. Miller resigned as a member of the Board of Directors of Genvor Incorporated (the Company).
お知らせ • Aug 16Genvor Incorporated announced delayed 10-Q filingOn 08/15/2024, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 18Genvor Incorporated Appoints Judith Miller as Chief Business OfficerGenvor Incorporated announced Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer.
お知らせ • Jan 17Genvor Incorporated Announces CEO ChangesGenvor Incorporated announced Chad Pawlak, Sr., global Agribusiness executive, has been appointed as Chief Executive Officer of Genvor, effective immediately. Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer. Chad Pawlak, Sr. brings over 30 years of experience with a proven track record of driving revenue growth and fostering strategic partnerships across agribusiness, regenerative agriculture, carbon marketing, food, and sustainability - particularly in soil and water conservation. He has a deep understanding of regenerative agriculture, biotechnology, crop cultivation, livestock management, dairy production, and consumer packaged goods (CPG). Most recently he was Chief Executive Officer of Locus Agricultural Solutions, an agricultural biological company, where he led the strategic growth plan through cross-functional collaboration, resulting in over 350,000 acres of enrollment in a nature-based carbon credit project utilizing a biological product as the practice change. Chad has previous experience as the U.S.-Canada Crop & Plant Protection Business Director Lead - Botanicals for MGK (a part of Valent USA & Sumitomo Chemical). In this role, he was responsible for the overall design of the strategic business plan of the $30 million Botanical & Organic Crop Protection segments in the U.S. & Canada. He holds an MBA from the Jack Welch Management Institute and BS & AOS in Marketing and Advertising/Public Relations from Johnson & Wales University.